A pre-clinical study using a combination of inhibitors of PRMT1 (MS023) and PRMT5 (EPZ015666) demonstrated an efficient anti-cancer effect in lung cancer and pancreatic cancer cell lines [109]. This evidence concerns the gene PRMT1 and cancer.